Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

@inproceedings{Jauw2017PerformanceO8,
  title={Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma},
  author={Yvonne W. S. Jauw and Jos{\'e}e M Zijlstra and Daphne D de Jong and Danielle J. Vugts and Sonja Zweegman and Otto S. Hoekstra and Guus A. M. S. van Dongen and Marc C. Huisman},
  booktitle={PloS one},
  year={2017}
}
PURPOSE Treatment of patients with diffuse large B cell lymphoma (DLBCL) includes rituximab, an anti-CD20 monoclonal antibody (mAb). Insufficient tumor targeting might cause therapy failure. Tumor uptake of 89Zirconium (89Zr)-mAb is a potential imaging biomarker for tumor targeting, since it depends on target antigen expression and accessibility. The aim of… CONTINUE READING